Mesenchymal stem cells and their use in therapy: What has been achieved?

Differentiation

Volumn 85, Issue 1-2, 2013, Pages 1-10

  Fernandez Vallone V B ^a,c   Romaniuk, M A ^a,d   Choi, H ^b,e   Labovsky, V ^a,c   Otaegui, J ^a,c   Chasseing, N A ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c not available   (Argentina)

^d not available   (Argentina)

^e NONE   (United States)

Author keywords

Bone marrow; Mesenchymal stem cells; Plasticity

Indexed keywords

5' NUCLEOTIDASE; CD11B ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD79A ANTIGEN; ENDOGLIN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; THY 1 ANTIGEN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ADIPOCYTE; ADIPOSE TISSUE; ANTIGEN EXPRESSION; BONE MARROW; CARTILAGE CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL LINEAGE; CELL RENEWAL; CELL TRANSDIFFERENTIATION; CEREBROVASCULAR ACCIDENT; CROHN DISEASE; CULTURE MEDIUM; CYTOKINE PRODUCTION; DIABETES MELLITUS; HEMATOPOIESIS; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; KIDNEY INJURY; MEDICAL SOCIETY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; OSTEOBLAST; OSTEOGENESIS IMPERFECTA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SPINAL CORD INJURY; TISSUE REGENERATION; TUMOR GROWTH;

BOVINAE;

EID: 84872246856     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2012.08.004     Document Type: Review

References (146)

1. Abrams M.B., Dominguez C., Pernold K., Reger R., Wiesenfeld-Hallin Z., Olson L., Prockop D. Multipotent mesenchymal stromal cells attenuate chronic inflammation and injury-induced sensitivity to mechanical stimuli in experimental spinal cord injury. Restorative Neurology and Neuroscience 2009, 27:307-321.
2. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
3. Alaiti M.A., Ishikawa M., Costa M.A. Bone marrow and circulating stem/progenitor cells for regenerative cardiovascular therapy. Translational Research 2010, 156:112-129.
4. Alhadlaq A., Mao J.J. Mesenchymal stem cells: isolation and therapeutics. Stem Cells and Development 2004, 13:436-448.
5. Alphonso A., Alahari S.K. Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia (New York, NY) 2009, 11:1264-1271.
6. Anonymous Myelofibrosis and the biology of connective tissue. Progress in Clinical and Biological Research 1984, 154:1-500.
7. Aranda P., Agirre X., Ballestar E., Andreu E.J., Roman-Gomez J., Prieto I., Martin-Subero J.I., Cigudosa J.C., Siebert R., Esteller M., Prosper F. Epigenetic signatures associated with different levels of differentiation potential in human stem cells. PLoS One 2009, 4:e7809.
8. Baksh D., Song L., Tuan R.S. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. Journal of Cellular and Molecular Medicine 2004, 8:301-316.
9. Barry F., Boynton R., Murphy M., Haynesworth S., Zaia J. The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochemical and Biophysical Research Communications 2001, 289:519-524.
10. Bernardo M.E., Zaffaroni N., Novara F., Cometa A.M., Avanzini M.A., Moretta A., Montagna D., Maccario R., Villa R., Daidone M.G., Zuffardi O., Locatelli F. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Research 2007, 67:9142-9149.
11. Bianco P., Robey P.G., Saggio I., Riminucci M. "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. Human Gene Therapy 2010, 21:1057-1066.
12. Bianco P., Sacchetti B., Riminucci M. Osteoprogenitors and the hematopoietic microenvironment. Best Practice and Research Clinical Haematology 2011, 24:37-47.
13. Boiret N., Rapatel C., Veyrat-Masson R., Guillouard L., Guerin J.J., Pigeon P., Descamps S., Boisgard S., Berger M.G. Characterization of nonexpanded mesenchymal progenitor cells from normal adult human bone marrow. Experimental Hematology 2005, 33:219-225.
14. Bruno S., Grange C., Deregibus M.C., Calogero R.A., Saviozzi S., Collino F., Morando L., Busca A., Falda M., Bussolati B., Tetta C., Camussi G. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. Journal of the American Society of Nephrology 2009, 20:1053-1067.
15. Buhring H.J., Battula V.L., Treml S., Schewe B., Kanz L., Vogel W. Novel markers for the prospective isolation of human MSC. Annals of the New York Academy of Sciences 2007, 1106:262-271.
16. Buhring H.J., Treml S., Cerabona F., de Zwart P., Kanz L., Sobiesiak M. Phenotypic characterization of distinct human bone marrow-derived MSC subsets. Annals of the New York Academy of Sciences 2009, 1176:124-134.
17. Caplan A.I. The mesengenic process. Clinics in Plastic Surgery 1994, 21:429-435.
18. Castro-Malaspina H., Gay R.E., Resnick G., Kapoor N., Meyers P., Chiarieri D., McKenzie S., Broxmeyer H.E., Moore M.A. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood 1980, 56:289-301.
19. Colter D.C., Class R., DiGirolamo C.M., Prockop D.J. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3213-3218.
20. Compston J.E. Bone marrow and bone: a functional unit. The Journal of endocrinology 2002, 173:387-394.
21. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V., Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
22. Chan J.L., Tang K.C., Patel A.P., Bonilla L.M., Pierobon N., Ponzio N.M., Rameshwar P. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006, 107:4817-4824.
23. Chang Y.J., Shih D.T., Tseng C.P., Hsieh T.B., Lee D.C., Hwang S.M. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells 2006, 24:679-685.
24. Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Human Gene Therapy 2010, 21:1045-1056.
25. Chen L., Zhang W., Yue H., Han Q., Chen B., Shi M., Li J., Li B., You S., Shi Y., Zhao R.C. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells and Development 2007, 16:719-731.
26. Chopp M., Li Y., Zhang Z.G. Mechanisms underlying improved recovery of neurological function after stroke in the rodent after treatment with neurorestorative cell-based therapies. Stroke 2009, 40:S143-145.
27. De Becker A., Van Hummelen P., Bakkus M., Vande Broek I., De Wever J., De Waele M., Van Riet I. Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 2007, 92:440-449.
28. Dexter T.M., Allen T.D., Lajtha L.G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. Journal of Cellular Physiology 1977, 91:335-344.
29. Dexter T.M., Wright E.G., Krizsa F., Lajtha L.G. Regulation of haemopoietic stem cell proliferation in long term bone marrow cultures. Biomedicine 1977, 27:344-349.
30. Dickhut A., Schwerdtfeger R., Kuklick L., Ritter M., Thiede C., Neubauer A., Brendel C. Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue. Annals of Hematology 2005, 84:722-727.
31. Ding Y., Xu D., Feng G., Bushell A., Muschel R.J., Wood K.J. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes 2009, 58:1797-1806.
32. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., Cantos C., Jorgensen C., Noel D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007, 25:2025-2032.
33. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D., Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
34. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
35. Eaves C.J., Cashman J.D., Sutherland H.J., Otsuka T., Humphries R.K., Hogge D.E., Lansdorp P.L., Eaves A.C. Molecular analysis of primitive hematopoietic cell proliferation control mechanisms. Annals of the New York Academy of Sciences 1991, 628:298-306.
36. Ezquer F., Ezquer M., Simon V., Pardo F., Yanez A., Carpio D., Conget P. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biology of Blood and Marrow Transplantation 2009, 15:1354-1365.
37. Fibbe W.E., Noort W.A. Mesenchymal stem cells and hematopoietic stem cell transplantation. Annals of the New York Academy of Sciences 2003, 996:235-244.
38. Fox J.M., Chamberlain G., Ashton B.A., Middleton J. Recent advances into the understanding of mesenchymal stem cell trafficking. British Journal of Haematology 2007, 137:491-502.
39. Galotto M., Berisso G., Delfino L., Podesta M., Ottaggio L., Dallorso S., Dufour C., Ferrara G.B., Abbondandolo A., Dini G., Bacigalupo A., Cancedda R., Quarto R. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Experimental Hematology 1999, 27:1460-1466.
40. Gang E.J., Bosnakovski D., Figueiredo C.A., Visser J.W., Perlingeiro R.C. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007, 109:1743-1751.
41. Ghannam S., Bouffi C., Djouad F., Jorgensen C., Noel D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Research and Therapy 2010, 1:2.
42. Gregory C.A., Prockop D.J., Spees J.L. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. Experimental Cell Research 2005, 306:330-335.
43. Gregory C.A., Singh H., Perry A.S., Prockop D.J. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. The Journal of Biological Chemistry 2003, 278:28067-28078.
44. Gregory C.A., Ylostalo J., Prockop D.J. Adult bone marrow stem/progenitor cells (MSCs) are preconditioned by microenvironmental "niches" in culture: a two-stage hypothesis for regulation of MSC fate. Science STKE 294 2005, e37.
45. Helmy K.Y., Patel S.A., Silverio K., Pliner L., Rameshwar P. Stem cells and regenerative medicine: accomplishments to date and future promise. Therapeutic Delivery 2010, 1:693-705.
46. Ho A.D., Wagner W., Franke W. Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 2008, 10:320-330.
47. Hofer E., Chudzinski-Tavassi A.M., Bullorsky O.E., Bordenave R.H., Chasseing N.A. MMPs and tissue inhibitors in conditioned mediums from bone marrow CFU-F of advanced lung and breast cancer patients. The Hematology Journal 2002, 3:57.
48. Honczarenko M., Le Y., Swierkowski M., Ghiran I., Glodek A.M., Silberstein L.E. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006, 24:1030-1041.
49. Horwitz E.M., Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit?. Cytotherapy 2008, 10:771-774.
50. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., Muul L., Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8932-8937.
51. Jacobsen K., Kravitz J., Kincade P.W., Osmond D.G. Adhesion receptors on bone marrow stromal cells: in vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and gamma-irradiated mice. Blood 1996, 87:73-82.
52. Janowska-Wieczorek A., Majka M., Ratajczak J., Ratajczak M.Z. Autocrine/paracrine mechanisms in human hematopoiesis. Stem Cells 2001, 19:99-107.
53. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
54. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., Reyes M., Lenvik T., Lund T., Blackstad M., Du J., Aldrich S., Lisberg A., Low W.C., Largaespada D.A., Verfaillie C.M. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
55. Jones E., McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford) 2008, 47:126-131.
56. Karp J.M., Leng Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4:206-216.
57. Kasper G., Glaeser J.D., Geissler S., Ode A., Tuischer J., Matziolis G., Perka C., Duda G.N. Matrix metalloprotease activity is an essential link between mechanical stimulus and mesenchymal stem cell behavior. Stem Cells 2007, 25:1985-1994.
58. Kasten P., Beyen I., Egermann M., Suda A.J., Moghaddam A.A., Zimmermann G., Luginbuhl R. Instant stem cell therapy: characterization and concentration of human mesenchymal stem cells in vitro. European Cells and Materials 2008, 16:47-55.
59. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., Battula V.L., Weil M., Andreeff M., Marini F.C. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27:2614-2623.
60. Kidd S., Spaeth E., Klopp A., Andreeff M., Hall B., Marini F.C. The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 2008, 10:657-667.
61. Kim D.H., Yoo K.H., Choi K.S., Choi J., Choi S.Y., Yang S.E., Yang Y.S., Im H.J., Kim K.H., Jung H.L., Sung K.W., Koo H.H. Gene expression profile of cytokine and growth factor during differentiation of bone marrow-derived mesenchymal stem cell. Cytokine 2005, 31:119-126.
62. Kim J., Kang J.W., Park J.H., Choi Y., Choi K.S., Park K.D., Baek D.H., Seong S.K., Min H.K., Kim H.S. Biological characterization of long-term cultured human mesenchymal stem cells. Archives of Pharmacal Research 2009, 32:117-126.
63. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I., Lazarus H.M. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. Journal of Clinical Oncology 2000, 18:307-316.
64. Koh S.H., Noh M.Y., Cho G.W., Kim K.S., Kim S.H. Erythropoietin increases the motility of human bone marrow-multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells and Development 2009, 18:411-421.
65. Korbling M., Estrov Z. Adult stem cells for tissue repair-a new therapeutic concept?. The New England Journal of Medicine 2003, 349:570-582.
66. Kortesidis A., Zannettino A., Isenmann S., Shi S., Lapidot T., Gronthos S. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 2005, 105:3793-3801.
67. Krause U., Harter C., Seckinger A., Wolf D., Reinhard A., Bea F., Dengler T., Hardt S., Ho A., Katus H.A., Kuecherer H., Hansen A. Intravenous delivery of autologous mesenchymal stem cells limits infarct size and improves left ventricular function in the infarcted porcine heart. Stem Cells and Development 2007, 16:31-37.
68. Krebsbach P.H., Kuznetsov S.A., Bianco P., Robey P.G. Bone marrow stromal cells: characterization and clinical application. Critical Reviews in Oral Biology and Medicine 1999, 10:165-181.
69. Kruse M., Rosorius O., Kratzer F., Bevec D., Kuhnt C., Steinkasserer A., Schuler G., Hauber J. Inhibition of CD83 cell surface expression during dendritic cell maturation by interference with nuclear export of CD83 mRNA. The Journal of Experimental Medicine 2000, 191:1581-1590.
70. Kuci S., Kuci Z., Kreyenberg H., Deak E., Putsch K., Huenecke S., Amara C., Koller S., Rettinger E., Grez M., Koehl U., Latifi-Pupovci H., Henschler R., Tonn T., von Laer D., Klingebiel T., Bader P. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 2010, 95:651-659.
71. La Russa V.F., Schwarzenberger P., Miller A., Agrawal K., Kolls J., Weiner R. Marrow stem cells, mesenchymal progenitor cells, and stromal progeny. Cancer Investigation 2002, 20:110-123.
72. Larson B.L., Ylostalo J., Prockop D.J. Human multipotent stromal cells undergo sharp transition from division to development in culture. Stem Cells 2008, 26:193-201.
73. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
74. Le Blanc K., Rasmusson I., Gotherstrom C., Seidel C., Sundberg B., Sundin M., Rosendahl K., Tammik C., Ringden O. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scandinavian Journal of Immunology 2004, 60:307-315.
75. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
76. Le Blanc K., Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. Journal of Internal Medicine 2007, 262:509-525.
77. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scandinavian Journal of Immunology 2003, 57:11-20.
78. Lee J.W., Fang X., Gupta N., Serikov V., Matthay M.A. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:16357-16362.
79. Lee R.H., Oh J.Y., Choi H., Bazhanov N. Therapeutic factors secreted by mesenchymal stromal cells and tissue repair. Journal of Cellular Biochemistry 2011, 112:3073-3078.
80. Lee R.H., Seo M.J., Reger R.L., Spees J.L., Pulin A.A., Olson S.D., Prockop D.J. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:17438-17443.
81. Lepelletier Y., Lecourt S., Renand A., Arnulf B., Vanneaux V., Fermand J.P., Menasche P., Domet T., Marolleau J.P., Hermine O., Larghero J. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells and Development 2010, 19:1075-1079.
82. Li H., Guo Z., Jiang X., Zhu H., Li X., Mao N. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 2008, 26:2531-2541.
83. Li J., Kwong D.L., Chan G.C. The effects of various irradiation doses on the growth and differentiation of marrow-derived human mesenchymal stromal cells. Pediatric Transplantation 2007, 11:379-387.
84. Maccario R., Podesta M., Moretta A., Cometa A., Comoli P., Montagna D., Daudt L., Ibatici A., Piaggio G., Pozzi S., Frassoni F., Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
85. Mackay A.M., Beck S.C., Murphy J.M., Barry F.P., Chichester C.O., Pittenger M.F. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Engineering 1998, 4:415-428.
86. Majumdar M.K., Thiede M.A., Mosca J.D., Moorman M., Gerson S.L. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. Journal of Cellular Physiology 1998, 176:57-66.
87. Matthay M.A. Advances and challenges in translating stem cell therapies for clinical diseases. Translational Research 2010, 156:107-111.
88. Mayani H., Guilbert L.J., Janowska-Wieczorek A. Biology of the hemopoietic microenvironment. European Journal of Haematology 1992, 49:225-233.
89. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., Macarthur B.D., Lira S.A., Scadden D.T., Ma'ayan A., Enikolopov G.N., Frenette P.S. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
90. Minguell J.J., Erices A., Conget P. Mesenchymal stem cells. Experimental Biology and Medicine (Maywood) 2001, 226:507-520.
91. Mueller S.M., Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. Journal of Cellular Biochemistry 2001, 82:583-590.
92. Muraglia A., Corsi A., Riminucci M., Mastrogiacomo M., Cancedda R., Bianco P., Quarto R. Formation of a chondro-osseous rudiment in micromass cultures of human bone-marrow stromal cells. Journal of Cell Science 2003, 116:2949-2955.
93. Myers T.J., Granero-Molto F., Longobardi L., Li T., Yan Y., Spagnoli A. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opinion on Biological Therapy 2010, 10:1663-1679.
94. Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
95. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. Journal of Immunology 2006, 177:2080-2087.
96. Neuhuber B., Swanger S.A., Howard L., Mackay A., Fischer I. Effects of plating density and culture time on bone marrow stromal cell characteristics. Experimental Hematology 2008, 36:1176-1185.
97. Ng F., Boucher S., Koh S., Sastry K.S., Chase L., Lakshmipathy U., Choong C., Yang Z., Vemuri M.C., Rao M.S., Tanavde V. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008, 112:295-307.
98. Parekkadan B., Milwid J.M. Mesenchymal stem cells as therapeutics. Annual Review of Biomedical Engineering 2010, 12:87-117.
99. Parekkadan B., Tilles A.W., Yarmush M.L. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 2008, 26:1913-1919.
100. Patel S.A., Sherman L., Munoz J., Rameshwar P. Immunological properties of mesenchymal stem cells and clinical implications. Archivum Immunologiae et Therapiae Experimentalis (Warsz) 2008, 56:1-8.
101. Pereira R.F., O'Hara M.D., Laptev A.V., Halford K.W., Pollard M.D., Class R., Simon D., Livezey K., Prockop D.J. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:1142-1147.
102. Pevsner-Fischer M., Levin S., Zipori D. The origins of mesenchymal stromal cell heterogeneity. Stem Cell Reviews 2011, 7:560-568.
103. Ponte A.L., Marais E., Gallay N., Langonne A., Delorme B., Herault O., Charbord P., Domenech J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007, 25:1737-1745.
104. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. Journal of Immunology 2003, 171:3426-3434.
105. Pountos I., Giannoudis P.V. Biology of mesenchymal stem cells. Injury 2005, 36(Suppl. 3):S8-S12.
106. Prindull G. Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells?. Experimental Hematology 2005, 33:738-746.
107. Prockop D.J. "Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). Clinical Pharmacology and Therapeutics 2007, 82:241-243.
108. Prockop D.J. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Molecular Therapy 2009, 17:939-946.
109. Prockop D.J. Defining the probability that a cell therapy will produce a malignancy. Molecular Therapy 2010, 18:1249-1250.
110. Prockop D.J., Brenner M., Fibbe W.E., Horwitz E., Le Blanc K., Phinney D.G., Simmons P.J., Sensebe L., Keating A. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 2010, 12:576-578.
111. Prockop D.J., Kota D.J., Bazhanov N., Reger R.L. Evolving paradigms for repair of tissues by adult stem/progenitor cells (MSCs). Journal of Cellular and Molecular Medicine 2010, 14:2190-2199.
112. Rasmusson I., Le Blanc K., Sundberg B., Ringden O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scandinavian Journal of Immunology 2007, 65:336-343.
113. Ren G., Su J., Zhang L., Zhao X., Ling W., L'Huillie A., Zhang J., Lu Y., Roberts A.I., Ji W., Zhang H., Rabson A.B., Shi Y. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009, 27:1954-1962.
114. Ren G., Zhao X., Zhang L., Zhang J., L'Huillier A., Ling W., Roberts A.I., Le A.D., Shi S., Shao C., Shi Y. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. Journal of Immunology 2010, 184:2321-2328.
115. Rougier F., Dupuis F., Denizot Y. Human bone marrow fibroblasts-an overview of their characterization, proliferation and inflammatory mediator production. Hematology and Cell Therapy 1996, 38:241-246.
116. Russell K.C., Phinney D.G., Lacey M.R., Barrilleaux B.L., Meyertholen K.E., O'Connor K.C. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010, 28:788-798.
117. Ruster B., Gottig S., Ludwig R.J., Bistrian R., Muller S., Seifried E., Gille J., Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
118. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., Tagliafico E., Ferrari S., Robey P.G., Riminucci M., Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
119. Schmidt A., Ladage D., Schinkothe T., Klausmann U., Ulrichs C., Klinz F.J., Brixius K., Arnhold S., Desai B., Mehlhorn U., Schwinger R.H., Staib P., Addicks K., Bloch W. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells 2006, 24:1750-1758.
120. Schwarz S.C., Schwarz J. Translation of stem cell therapy for neurological diseases. Translational Research 2010, 156:155-160.
121. Sekiya I., Larson B.L., Smith J.R., Pochampally R., Cui J.G., Prockop D.J. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002, 20:530-541.
122. Shaker A., Rubin D.C. Intestinal stem cells and epithelial-mesenchymal interactions in the crypt and stem cell niche. Translational Research 2010, 156:180-187.
123. Simmons P.J., Przepiorka D., Thomas E.D., Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987, 328:429-432.
124. Sorrentino A., Ferracin M., Castelli G., Biffoni M., Tomaselli G., Baiocchi M., Fatica A., Negrini M., Peschle C., Valtieri M. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Experimental Hematology 2008, 36:1035-1046.
125. Steingen C., Brenig F., Baumgartner L., Schmidt J., Schmidt A., Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. Journal of Molecular and Cellular Cardiology 2008, 44:1072-1084.
126. Sueblinvong V., Weiss D.J. Stem cells and cell therapy approaches in lung biology and diseases. Translational Research 2010, 156:188-205.
127. Taichman R.S., Emerson S.G. The role of osteoblasts in the hematopoietic microenvironment. Stem Cells 1998, 16:7-15.
128. Tamama K., Fan V.H., Griffith L.G., Blair H.C., Wells A. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells 2006, 24:686-695.
129. Tocci A., Forte L. Mesenchymal stem cell: use and perspectives. The Hematology Journal 2003, 4:92-96.
130. Togel F., Westenfelder C. Stem cells in acute kidney injury repair. Minerva Urologica e Nefrologica 2009, 61:205-213.
131. Tuli R., Tuli S., Nandi S., Huang X., Manner P.A., Hozack W.J., Danielson K.G., Hall D.J., Tuan R.S. Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk. The Journal of Biological Chemistry 2003, 278:41227-41236.
132. Uccelli A., Prockop D.J. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?. Current Opinion in Immunology 2010, 22:768-774.
133. Van Overstraeten-Schlogel N., Beguin Y., Gothot A. Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. European Journal of Haematology 2006, 76:488-493.
134. Wagers A.J., Weissman I.L. Plasticity of adult stem cells. Cell 2004, 116:639-648.
135. Wang Q.R., Wang B.H., Zhu W.B., Huang Y.H., Li Y., Yan Q. An in vitro study of differentiation of hematopoietic cells to endothelial cells. Bone Marrow Research 2011, 2011:846096-846104.
136. Wang R., Stromer M.H., Huiatt T.W. Integrin expression in developing smooth muscle cells. The Journal of Histochemistry and Cytochemistry 1998, 46:119-126.
137. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010, 5:e10088.
138. Whetton A.D., Dexter T.M. Influence of growth factors and substrates on differentiation of haemopoietic stem cells. Current Opinion in Cell Biology 1993, 5:1044-1049.
139. Wong R.S. Mesenchymal stem cells: angels or demons?. Journal of Biomedicine and Biotechnology 2011, 2011:459510-459517.
140. Yagi H., Soto-Gutierrez A., Parekkadan B., Kitagawa Y., Tompkins R.G., Kobayashi N., Yarmush M.L. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplantation 2010, 19:667-679.
141. Yamada M., Suzu S., Tanaka-Douzono M., Wakimoto N., Hatake K., Hayasawa H., Motoyoshi K. Effect of cytokines on the proliferation/differentiation of stroma-initiating cells. Journal of Cellular Physiology 2000, 184:351-355.
142. Ylostalo J., Bazhanov N., Prockop D.J. Reversible commitment to differentiation by human multipotent stromal cells in single-cell-derived colonies. Experimental Hematology 2008, 36:1390-1402.
143. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
144. Zhou D.H., Huang S.L., Wu Y.F., Wei J., Chen G.Y., Li Y., Bao R. The expansion and biological characteristics of human mesenchymal stem cells. Zhonghua Er Ke Za Zhi 2003, 41:607-610.
145. Zipori D. Mesenchymal stem cells: harnessing cell plasticity to tissue and organ repair. Blood Cells, Molecules and Diseases 2004, 33:211-215.
146. Zorn A.M. Wnt signalling: antagonistic Dickkopfs. Current Biology 2001, 11:R592-595.